For the current clinical utilisation of PTBP1, Qian et al. [47] in 2020 described an antisense oligonucleotide that inhibits PTBP1 and converts astrocytes into new neurons, which identifies a potentially and powerful new clinically viable approach to treat neurodegenerative diseases such as Parkinson’s by replacing lost neurons. Here, PTBP1 is linked to Parkinsonism.